Development and application of high throughput plasma stability assay for drug discovery

被引:158
作者
Di, L [1 ]
Kerns, EH [1 ]
Hong, Y [1 ]
Chen, H [1 ]
机构
[1] Wyeth Ayerst Res, Princeton, NJ 08543 USA
关键词
plasma stability; stability; hydrolysis; prodrugs; enzymes; HPLC; LC-MS; high throughput;
D O I
10.1016/j.ijpharm.2005.03.022
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Plasma stability plays an important role in drug discovery and development. Unstable compounds tend to have rapid clearance and short half-life, resulting in poor in vivo performance. This paper examines the variables that affect the plasma stability assay results, including substrate concentration, %DMSO, plasma concentration, enzyme activity upon incubation and batch variation. The results show that plasma stability can accommodate a wide range of experimental conditions. Relatively minor differences in results are produced with major differences in conditions. Significant batch-to-batch variations were observed for rat plasma. We selected the following conditions: 1 mu M substrate concentration, 2.5% DMSO, and 50% dilution of plasma in pH 7.4 buffer. Plasma stability can be used as a diagnostic assay when compounds are unexpectedly rapidly cleared, as a special assay when structural classes contain groups that may be susceptible to plasma enzyme hydrolysis, or as general screen for compounds if resources are available. Plasma stability assay has many applications in drug discovery: to alert teams to labile structural motifs, to prioritize compounds for in vivo studies and to screen prodrugs and antedrugs. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:110 / 119
页数:10
相关论文
共 26 条
[1]
Design and synthesis of pyrrolidine-5,5′-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease.: 4.: Antiviral activity and plasma stability [J].
Borthwick, AD ;
Davies, DE ;
Ertl, PF ;
Exall, AM ;
Haley, TM ;
Hart, GJ ;
Jackson, DL ;
Parry, NR ;
Patikis, A ;
Trivedi, N ;
Weingarten, GG ;
Woolven, JM .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (21) :4428-4449
[2]
Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease.: Part 3:: Potency and plasma stability [J].
Borthwick, AD ;
Exall, AM ;
Haley, TM ;
Jackson, DL ;
Mason, AM ;
Weingarten, GG .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (13) :1719-1722
[3]
Structure-based optimization of novel azepane derivatives as PKB inhibitors [J].
Breitenlechner, CB ;
Wegge, T ;
Berillon, L ;
Graul, K ;
Marzenell, M ;
Friebe, WG ;
Thomas, U ;
Schumacher, R ;
Huber, R ;
Engh, RA ;
Masjost, B .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (06) :1375-1390
[4]
Busby WF, 1999, DRUG METAB DISPOS, V27, P246
[5]
Chauret N, 1998, DRUG METAB DISPOS, V26, P1
[6]
Experimental design on single-time-point high-throughput microsomal stability assay [J].
Di, L ;
Kerns, EH ;
Gao, N ;
Li, SQ ;
Huang, YP ;
Bourassa, JL ;
Huryn, DM .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (06) :1537-1544
[7]
Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates [J].
Di, L ;
Kerns, EH ;
Hong, Y ;
Kleintop, TA ;
McConnell, OJ ;
Huryn, DM .
JOURNAL OF BIOMOLECULAR SCREENING, 2003, 8 (04) :453-462
[8]
Profiling drug-like properties in discovery research [J].
Di, L ;
Kerns, EH .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2003, 7 (03) :402-408
[9]
DI L, 2005, IN PRESS DEV APPL AU
[10]
Lessons learned from marketed and investigational prodrugs [J].
Ettmayer, P ;
Amidon, GL ;
Clement, B ;
Testa, B .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2393-2404